Strides Pharma ScienceNSE:STAR +2.95%67 PS Ratio is 2.14 as of Jul. 02, 2026, which is 128% above its 10-year median of 0.94. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹775.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 950 Drug Manufacturers companies, Strides Pharma Science ranks better than 52.53% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Strides Pharma Science's share price is ₹1126.40.
Strides Pharma Science's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹527.13. Hence, Strides Pharma Science's PS Ratio for today is 2.14.
Warning Sign:
Strides Pharma Science Ltd stock PS Ratio (=2.05) is close to 10-year high of 2.19.
The historical rank and industry rank for Strides Pharma Science's PS Ratio or its related term are showing as below:
NSE:STAR'
s PS Ratio Range Over the Past 10 Years
Min: 0.32 Med: 0.94 Max: 2.19
Current: 2.09
During the past 13 years, Strides Pharma Science's highest PS Ratio was 2.19. The lowest was 0.32. And the median was 0.94.
NSE:STAR's PS Ratio is ranked better than 52.53% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs NSE:STAR: 2.09
During the past 12 months, the average Revenue per Share Growth Rate of Strides Pharma Science was 6.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.00% per year.
During the past 13 years, Strides Pharma Science's highest 3-Year average Revenue per Share Growth Rate was 30.20% per year. The lowest was -17.80% per year. And the median was 9.35% per year.
Back to Basics: PS Ratio
Strides Pharma Science (NSE:STAR) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's PS Ratio distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Strides Pharma Science's Share Price of today is ₹1126.40. Strides Pharma Science's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹527.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Strides Pharma Science (NSE:STAR) has a PS Ratio of 2.14 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Strides Pharma Science and its competitors. This is 128% above median its historical median of 0.94. Over the past decade, Strides Pharma Science's PS Ratio has ranged from 0.32 to 2.19. According to the industry distribution chart, Strides Pharma Science ranks #451 out of 950 companies in the Drug Manufacturers industry, placing it in the top 47.5%.
Is Strides Pharma Science's PS Ratio too high?
Strides Pharma Science's current PS Ratio of 2.14 is 128% above median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 2.19. The Drug Manufacturers industry median PS Ratio is 2.27. Strides Pharma Science's value of 2.14 is 5.7% below this industry median. Based on the distribution chart, Strides Pharma Science ranks #451 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #451 out of 950 companies for PS Ratio. This puts Strides Pharma Science in the upper half of its industry. The industry median PS Ratio is 2.27. Strides Pharma Science's value of 2.14 is 5.7% below this benchmark. Historically, Strides Pharma Science's own PS Ratio has ranged from 0.32 to 2.19 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 2.27, Strides Pharma Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.27, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current PS Ratio of 2.14 is 5.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current PS Ratio is 2.14, which is 128% above median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹775.59, compared to a current price of ₹1,126.40 — trading 45.2% above its estimated fair value. The current PS Ratio is 2.14, which is 128% above median its 10-year median of 0.94 and 5.7% below the Drug Manufacturers industry median of 2.27. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current PS Ratio is 2.14 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,126.40 is trading 45.2% above its estimated GF Value™ of ₹775.59.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
PS Ratio: 2.14 (128% above median its 10-year median of 0.94)
GF Value™: ₹775.59 vs. price of ₹1,126.40 (45.2% above fair value)
Industry Position: 5.7% below the Drug Manufacturers median (#451 of 950)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score
Get the complete analysis for NSE:STAR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
